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Background. The Gambia was the ﬁrst country in Africa to introduce conjugate Haemophilus inﬂuenzae type b
(Hib) vaccine, which, as in other developing countries but unlike industrialized countries, is delivered as a 3-dose
primary series with no booster. This study assessed its effectiveness 14 years after introduction.
Methods. Using methods standardized during >20 years in the study site, clinical and microbiological surveil-
lance for invasive Hib disease (primarily meningitis) in the Western Region of The Gambia from 2007 to 2010 was
complemented with studies of Hib carriage in children aged 1 to <2 years, Hib antibody levels in children aged <5
years, and Hib vaccine coverage and timing in children aged 1 to <2 years.
Results. The incidence of Hib meningitis remained low (averaging 1.3 per 100 000 children aged <5 years annu-
ally), as did the Hib oropharyngeal carriage rate (0.9%). Hib antibody levels were protective in >99% of those sur-
veyed, albeit with lower titers in older children; and coverage of conjugate Hib vaccination was high (91% having 3
doses at 1–2 years of age) using a schedule that was delivered at median ages of 2.6 months, 4.3 months, and 6
months for the ﬁrst, second, and third doses, respectively.
Conclusions. Conjugate Hib vaccine was delivered on time in a 3-dose primary series without booster to a high
proportion of eligible children and this was associated with effective disease control up to 14 years after introduc-
tion. It is important that surveillance continues in this ﬁrst African country to introduce the vaccine to determine if
effective control persists or if a booster dose becomes necessary as has been the case in industrialized countries.
Keywords. Hib vaccination; Hib disease; surveillance; Gambia; Africa.
Invasive Haemophilus inﬂuenzae type b (Hib) disease,
an important cause of meningitis, pneumonia and sep-
ticemia, is a major contributor to childhood morbidity
and mortality in unvaccinated populations, most of
which are in developing countries [1]. The Gambia was
the ﬁrst country in Africa to routinely vaccinate its chil-
dren with conjugate Hib vaccine, beginning in 1997
using a primary series of 3 doses scheduled for children
aged 2, 3, and 4 months and no booster dose, and this
schedule remains unchanged. Using consistent surveil-
lance methods focusing primarily on the detection of
Hib meningitis, we reported the virtual disappearance
of invasive Hib disease from The Gambia by 2002 [2],
and its presence at a very low incidence thereafter [3].
The most pressing question for African and many
other developing countries is whether a booster dose
will be needed in the long term, and the experience in
The Gambia is highly relevant to this question.
The rollout of Hib vaccine worldwide has been rapid
in the last 15 years [4]. In 1997, just 15% of countries
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had introduced the vaccine [5], and >80% of countries world-
wide were using it by 2010 [5], increasing to 92% in 2012 [6].
Importantly, >80% of GAVI Alliance support-eligible developing
countries were using Hib vaccine by 2010 [7, 8].Most industrial-
ized countries have a booster dose in their routine schedule, but
developing countries typically do not [9], which is consistent
with World Health Organization (WHO) policy [10].
Apart from invasive Hib disease incidence data, vaccine cov-
erage data, Hib carriage data, and community Hib antibody
data give useful insights into the dynamics of Hib transmission
and protection. In The Gambia, the prevalence of Hib carriage
in children aged 1 to <2 years before routine vaccination was
introduced was 12%, and this dropped to 0.25% by 2002. In
2000 the proportions of children aged 1 to <2 years having re-
ceived 3 doses of vaccine were 68%, 2 doses 84%, and 1 dose
94%. The median age of children at vaccination was 3.4 months,
6.5 months, and 8 months for the ﬁrst, second, and third
doses, respectively. The vaccine preparation in which conju-
gate Hib vaccine is delivered changed midway through the sur-
veillance period in June 2009 from quadrivalent diphtheria/
tetanus/pertussis/Hib to pentavalent diphtheria/tetanus/per-
tussis/hepatitis B/Hib. Both preparations are from the Serum
Institute of India and contain the PRP-T conjugated Hib
antigen and whole cell pertussis. In addition to formal clinical
and microbiological monitoring of disease in The Gambia
between 2007 and 2010 [3], a number of other investigations
of carriage, community seroprotection, and vaccine coverage
and timing were done to explore the question of the vaccine’s
long-term effectiveness in this setting further, and these are re-
ported here.
MATERIALS ANDMETHODS
As elsewhere described [3], surveillance was carried out
between 22 October 2007 and 31 December 2010 in the same
area and using the same methods as used and reported previ-
ously [2]. Patients with suspected invasive Hib disease present-
ing to study hospitals were investigated by culture, and
particular emphasis was placed on the detection of Hib meningi-
tis by culture of cerebrospinal ﬂuid and blood. Surveillance was
undertaken in the Western Region of The Gambia (Figure 1),
which had a total population of 836 000 in the 2003 census (60%
of the population of The Gambia) and comprises urban, periur-
ban, and rural areas. The population aged <5 years in this area
was 100 000 in 2003 (census data) and was estimated to have a
mean of 128 000 in the calendar years 2008–2010.
In addition to disease surveillance, investigations of Hib car-
riage, community Hib antibody levels, and Hib vaccine cover-
age were undertaken, and the methods for these are described
here.
Figure 1. Map of The Gambia showing the Western Region study area (shaded) containing study hospitals in Fajara, Banjul, and Sibanor. Abbreviations:
MRC, Medical Research Council; RVTH, Royal Victoria Teaching Hospital.
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Carriage Study
One thousand children aged 1 to <2 years, 500 each from
urban (Fajikunda and Serekunda) and rural (Sibanor) well-
child clinics, were investigated for Hib carriage, using the same
methods as previously used [2],. All children in the target age
range presenting to the clinic were eligible for recruitment re-
gardless of vaccination status. These children had oropharyn-
geal swabbing done by 2 trained ﬁeld workers. The swabs were
plated onto Hib antiserum plates and placed in standard
fashion in a candle-containing jar and transported to the mi-
crobiology laboratory at the Medical Research Council Unit,
Fajara. We estimated that 874 participants would be required to
detect a rise of carriage prevalence from 0.25% (the 2000–2001
level) to 2% with a power of 90% and a 5% signiﬁcance level.
New carriage rates were compared with carriage rates obtained
in 2000–2001 [2].
Antibody Survey
Hib antibody levels were measured for 3 different age groups
(1 to <2 years, 2 to <3 years, and 3 to <5 years) to assess immu-
nity by age. The aim was to recruit 250 children in each group,
giving 90% power at a 5% signiﬁcance level to detect a diffe-
rence in proportion of children having a protective antibody
level (>0.15 µg/mL) of 70% in the 1- to <2-year age group and
55% in either of the other groups.
Hib antibody assays were performed at the Murdoch Child-
ren’s Research Institute, Victoria, Australia, following established
methods [11–14]. Microtiter plates were coated with H. inﬂuen-
zae Type B Oligosaccharide–Human Serum Albumin Conjugate
(BEI Resources, Manassas, Virginia). The standard, anti-Hib cap-
sular polysaccharide serum (lot 1983; FDA, Kensington, Mary-
land), control anti-Hibhuman reference serum (National Institute
for Biological Standards and Control, UK), and patient samples
were incubated on precoated plates. Horseradish peroxidase–
conjugated anti-human immunoglobulin G (Millipore, Australia)
and a tetramethylbenzidine (TMB) substrate solution (KPL, Gai-
thersburg, Maryland) were subsequently added to the plates for
detection. The optical density of each well was read on the micro-
plate reader at 450 nm (reference ﬁlter 630 nm). Optical density
data were converted to antibody concentrations with KCjunior
software (Bio-Tek Instruments Inc). Results were calculated using
a standardized curve-ﬁtting 4-parameter logistic method.
Logarithms of Hib antibody levels and geometric mean anti-
body titers and their 95% conﬁdence intervals (CIs) were calcu-
lated. Logistic and linear regression was used to estimate
differences in Hib seropositivity (as deﬁned by >0.15 or 1 µg/
mL) and log titers between areas of residence and age groups.
Statistical analyses were performed using Stata statistical soft-
ware version 12.0 (StataCorp, College Station, Texas).
Vaccine Coverage and Timing
Vaccine coverage was assessed in 1 to <2 years olds using the
cluster survey technique recommended by WHO [15]. A
cluster was deﬁned as ≥7 children in the target age range. The
coverage estimate has a 95% conﬁdence level of ±10%. The
survey, which consisted of visiting homes and examining im-
munization records of children, was carried out in June 2010 in
120 clusters, 30 clusters being systematically selected in each of
the Banjul, Kaniﬁng, Kombos, and Fonis districts across the
study area. Fieldworkers visited at least 7 children’s homes in
each cluster to collect data on their immunization status against
measles, yellow fever, polio, tuberculosis, tetanus, diphtheria,
pertussis, hepatitis B, and Hib.
RESULTS
Details of the incidence of invasive Hib disease in the study
period, which remained low at an average of 1.3 cases of Hib
Figure 2. Incidence of Haemophilus inﬂuenzae type b (Hib) meningitis in children <5 years of age, cases per 100 000 per year, in the Western Region of
The Gambia from 1990 to 2010.
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meningitis per 100 000 children aged <5 years annually, have
been reported elsewhere (Figure 2) [3]. The total number of
cases seen was 9, with 3 having had ≥2 doses of vaccine, 4
having 0–1 dose, and 2 having an unknown number of doses.
Four cases occurred before the introduction of the pentavalent
preparation midway through the study period and 5 after. The
median age of patients was 5 months (range, 3–13 months),
and they were evenly divided between meningitis cases (n = 5)
and septicemia cases with no evidence of meningitis (n = 4).
Hib Carriage
The carriage study was conducted between April 2009 and Feb-
ruary 2010. The median age of the children recruited was 18.5
months (range, 12–22 months). Nine isolates of Hib were ob-
tained from oropharyngeal swabs, giving a carriage prevalence
of 0.9% (95% CI, .3%–1.5%), compared to 0.25% (95% CI,
.06%–.9%) in 2002 (P = .28). Figure 3 shows current and histor-
ical carriage rates in urban and rural locations.
Hib Antibodies
The Hib antibody survey was carried out between May 2009
and April 2010. Seven hundred sixty-two children were includ-
ed, 419 (55%) rural (Sibanor) and 343 (45%) urban (Serekunda
and Fajikunda). Across the 3 age bands, the numbers enrolled
were 239 (31%) aged 1 to <2 years, 249 (33%) aged 2 to <3
years, and 272 (36%) aged 3 to <5 years. Two children had
missing dates of birth, so their ages could not be calculated.
Overall, 99.3% of the participants had antibody concentrations
of ≥0.15 µg/mL, and proportions were similar across age
groups and areas of residence. The overall geometric mean Hib
antibody concentration was 2.25 (95% CI, 2.07–2.45). The
details of antibody levels by age and area of residence are
shown in Table 1. There were no differences between the 2
urban sites, so their data have been combined. Higher levels of
antibodies to Hib were associated with urban compared to
rural residency; Hib antibody levels in the urban areas were
42% (95% CI, 20%–68%; P < .001) higher than those at the
rural area. Antibody levels to Hib were 22% (95% CI, 4%–36%;
P = .02) lower in the 3- to <5-year age group compared to those
in the 1- to <2-year age group. There was no evidence for a dif-
ference in antibody levels to Hib between those aged 1 to <2
years and those aged 2 to <3 years (P = .09). Overall, 75% (95%
CI, 72%–78%) had concentrations >1 µg/mL. The proportion
with Hib antibody concentrations >1 µg/mL were also higher
for those from the urban areas compared to the rural area (ad-
justed odds ratio [AOR], 1.60 [95% CI, 1.14–2.26], P = .007).
No difference was observed between the proportions fully vac-
cinated in urban (98.5%) and rural (97.5%) groups (P = .32).
Being older was associated with lower odds of concentrations
>1 µg/mL (AOR for 2 years vs 1 year, 0.6 [95% CI, .39–.94],
and 3 years vs 1 year, 0.5 [95% CI, .31–.72]).
Hib Vaccine Coverage and Timing
Nine hundred thirty-two children aged 1 to <2 years were
visited in 120 clusters in the Western Health Region of The
Gambia in June 2010. All but 1 of the 932 children surveyed
had their vaccination record cards available. Overall, 91% of the
children had received 3 doses of Hib vaccine, 96% 2 doses, and
98% 1 dose. The median age of children at the ﬁrst, second, and
third doses was 2.6 months (interquartile range [IQR], 2.2–3.3
Figure 3. Temporal trends in Haemophilus inﬂuenzae type b (Hib) carriage in children aged 12–23 months in rural (Sibanor) and urban (Serekunda/Faji-
kunda) settings.
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months), 4.3 months (IQR, 3.6–5.1 months), and 6.0 months
(IQR, 5.0–7.5 months,) respectively.
DISCUSSION
In the period 2007–2010, the incidence of Hib meningitis and
all invasive Hib disease remained low in the context of a
routine primary series of conjugate Hib vaccine without a
booster. Vaccine coverage was >90% for DTP3 (3 doses of
diphtheria-tetanus-pertussis vaccines) and the doses were given
without substantial delay. Hib carriage remained low but not
absent at 0.9% in children aged 1 to <2 years. Hib antibody
levels were at or above a putative protective level of 0.15 µg/mL
in >99% of children aged <5 years surveyed, although a decline
in antibody levels with advancing age was noted. These data
point to ongoing effective control and the need for vigilance to
ensure this continues.
Although almost all industrialized countries have introduced
Hib vaccine with a booster in addition to a primary series
[16, 17], there are other experiences of good control from a
primary series alone, including in African countries. In South
Africa, the incidence of disease reduced markedly after vaccine
introduction in 1999 [18]. Between 2003 and 2009, invasive
Hib disease increased, albeit at modest levels, from 0.7 to
1.3 per 100 000 children aged <5 years [19]. A booster dose was
introduced in 2010 in combination with inactivated polio
vaccine, but polio control was the driver for this, not Hib
disease. The incidence of Hib meningitis reported from Kenya
in children aged <5 years decreased, from 71 to 8 per 100 000
after vaccine introduction in 2001 [20], and has not risen since
(Anthony Scott, written personal communication, March 2013).
The vaccine was introduced into Malawi and Uganda in 2002,
and although no population-based incidence estimates are avail-
able, the reported number of hospital cases markedly decreased,
and had been sustained through 2009–2010 [9, 21]. Chile, Co-
lombia, and Brazil have all maintained good control without a
booster dose, with vaccine introductions occurring in 1996, 1998,
and 1999, respectively [22–24].
Good long-term control, however, has not been the experience
of all countries that have started with a 3-dose primary series
alone. The United Kingdom introduced Hib vaccine in 1993 and
was one of the few industrialized countries not to schedule a
booster dose from the outset. Control was excellent initially [25]
and carriage was eliminated [26], but after several years a resur-
gence of disease prompted the introduction of a booster dose in
2003, which was associated with a return to good control [25].
The introduction of a new and less immunogenic formulation
including acellular pertussis vaccine may have played a role in
waning immunity [27]. The United Kingdom differed from The
Gambia in a number of potentially relevant respects also, includ-
ing by having a lower preintroduction Hib carriage prevalenceTa
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and a higher median age of disease and by accompanying in-
troduction with a catch-up campaign [28]. Ireland appears to
have had a similar experience to the United Kingdom [29]. A
continuing postintroduction low level of Hib carriage and
transmission in The Gambia, not seen in the United Kingdom,
may provide an immunological stimulus that boosts communi-
ty protection and reduces the chances of a booster dose being
required.
The putative protective level of Hib antibody is regarded as
being 0.15 µg/mL [30], and no differences were observed
between sites or age groups for the proportions of participants
with these levels, which were extremely high. Some regard a
level of >1 µg/mL as being indicative of longer-term protection,
although this is not clear-cut [13, 14]. At this higher level,
which was achieved in 75% of children overall, some differences
were observed, most notably that this proportion dropped from
83% in 1-year-olds to 69% in 3- and 4-year-olds. The median
age of cases in The Gambia is <12 months [2, 3], but were the
epidemiology of invasive Hib disease to change by an increase
in the age of cases, this waning might become important. The
reason for the observed difference in antibody levels between
urban and rural areas is not clear. Differences in environmental
factors and host factors, such as nutritional status, may play a
part, although this study did not address this question. A
higher prevalence of HIV infection in the rural area of the
study has been observed [31] but the signiﬁcance of this for
community Hib seroprotection is unknown. What is also
unknown is whether the observed difference has public health
signiﬁcance, a question that can be addressed with continuing
surveillance.
A potential weakness of this study is that it is likely that cases
have been missed, a weakness shared by all surveillance studies.
Hospital-based surveillance underrepresents the incidence of
disease in the community, as not all patients will seek hospital
care, and this is particularly so for less severe disease. The efﬁ-
cacy of Hib vaccine has been shown to be similar against Hib
meningitis and Hib pneumonia; while Hib meningitis is the form
of invasive Hib disease most reliably diagnosed using routine
clinical management supported by sound bacteriology [32]. In
view of this, an emphasis on meningitis cases has been a delib-
erate measure to minimize ﬂuctuations in the sensitivity of sur-
veillance and give as robust an indication of long-term patterns
of control as possible. Although antibody concentrations were
assessed, antibody avidity was not, and this may have provided
a further insight into community seroprotection. A key strength
of this study is that it used the same surveillance methods as
previously used in this study area [2], and this has yielded com-
parable data spanning 20 years (Figure 1). Additionally, all the
methods used for the carriage, serology, and vaccine coverage
studies were accepted standard methods that have been used in
previous studies here, enhancing the comparability of data
through time.
The high proportion of countries (93% in 2012) [6] that have
introduced conjugate Hib vaccination does not reﬂect the pro-
portion of the world’s children being protected by Hib vaccine,
which is much lower. This is primarily because several high-
burden, high-population countries have yet to introduce the
vaccine, notably China and the Russian Federation, or have not
yet introduced the vaccine universally, such as in Nigeria and
India [4]. In Nigeria and India the vaccine has recently been in-
troduced into some regions after years of debate and advocacy
[4, 33–36]. It is currently estimated that 45% of the world’s
infants live in countries that have not introduced the vaccine,
and 52% of infants worldwide are not receiving Hib vaccine
[4]. Protecting these children remains a top global health priority.
The experience of invasive Hib disease control in The
Gambia 14 years after vaccine introduction is encouraging. The
good control seen in African countries introducing the vaccine
after The Gambia is also encouraging. The global experience of
conjugate Hib vaccine shows that it has been a highly successful
public health intervention [37]. However, it is well recognized
that the effectiveness of control can wane, and for this reason it
is very important that surveillance be maintained for its global
as well as local relevance.
CONCLUSIONS
In the period of this study, no evidence emerged to support the
introduction of a booster dose of conjugate Hib vaccine into
the Gambian Expanded Programme on Immunisation (EPI).
The incidence of invasive Hib disease remained low (average
1.3 Hib meningitis episodes per 100 000 children aged <5 years
annually); the Hib nasopharyngeal carriage rate in children
aged 1 to <2 years remained low (0.9%); Hib antibody levels in
young children were high, with >99% of those surveyed having
protective levels; and coverage of conjugate Hib vaccination
was high (91% having 3 doses at 1 to <2 years of age) using a
primary 3-dose schedule that was conﬁrmed to be a primary
series in practice as well as in theory. A decline in antibody
levels with age was observed. These data together conﬁrm that
the EPI was delivering the primary conjugate Hib vaccine series
on time to a high proportion of eligible children and that this
was associated with effective disease control in the period
studied. It is important that surveillance be continued to deter-
mine if effective control persists or whether control and immu-
nity wane and a booster dose becomes necessary.
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